AnGes has acquired 1 company, including 1 in the last 5 years.
AnGes’ largest acquisition to date was in 2020, when it acquired EmendoBio for $250M. AnGes has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).
Saito Bio-Incubator, 1st Floor 7-7-15, Saito-asagi,
Ibaraki,
567-0085
Japan,
www.anges.co.jp
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2020-12-15 |
EmendoBio, Inc. · Life Science
New York, New York · www.emendobio.com EmendoBio, Inc. is a CRISPR gene-editing company leveraging dual proprietary technology platforms to enable high precision gene-editing throughout the genome. EmendoBio’s novel nuclease discovery platform broadens the targetable range of the genome while its target‐specific optimization platform enables highly precise editing, including allele-specific editing while maintaining high efficiencies. EmendoBio is based in New York City. Advisor: Morgan Lewis |
250 | Add-on Acquisition | - |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
